Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.’s share was trading at $34.81 as of June 1st.
Likoper/Shutterstock.com
Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Its lead asset bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 assets, expanding its optionality across solid tumors and hematologic malignancies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Investors see peak sales potential exceeding 3 billion dollars for bezuclastinib alone, which underpins the market’s mispricing argument. In second-line GIST, bezuclastinib plus Sutent demonstrated a median progression-free survival of 16.5 months versus 9.2 months for standard of care, supporting meaningful efficacy differentiation. A Phase II first-line GIST study targeting exon 9 mutations expands the addressable market, while the NDA for second-line GIST is under RTOR with potential near-term approval.
In indolent systemic mastocytosis, the NDA has been accepted with a December 2026 PDUFA, representing a large and competitive commercial opportunity with over 500 million dollars in projected 2032 sales. In advanced systemic mastocytosis, submission is expected imminently with approximately 225 million dollars in projected 2032 sales and competitive positioning versus Ayvakit. Despite safety considerations in indolent disease potentially limiting share, the company’s efficacy profile and breadth of indication support strong overall uptake potential.
Strategically, Cogent is viewed as a prime M&A target, with bezuclastinib offering immediate integration potential into large oncology franchises seeking dominance in GI oncology and hematology space. The combination of de-risked clinical data, multiple near-term regulatory catalysts, and multi-indication peak sales exceeding 3 billion dollars creates a compelling risk-reward profile with substantial upside potential.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, gene editing pipeline, and strong cash position. CRSP’s stock price has appreciated by approximately 32.26% since our coverage. @seedy19tron shares a similar view but emphasizes Cogent Biosciences’ KIT-driven oncology assets, near-term regulatory catalysts, and M&A optionality driving >$3B peak sales upside.
